Home » Stocks » BLU

BELLUS Health Inc. (BLU)

Stock Price: $3.66 USD 0.20 (5.78%)
Updated Jan 15, 2021 9:45 AM EST - Market open
Market Cap 270.05M
Revenue (ttm) 12,030
Net Income (ttm) -28.14M
Shares Out 60.44M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $3.66
Previous Close $3.46
Change ($) 0.20
Change (%) 5.78%
Day's Open 3.49
Day's Range 3.47 - 3.67
Day's Volume 255,463
52-Week Range 2.14 - 12.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 weeks ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), announces that it has entered today into an agreement (the “Sales Agreement”) with ...

Business Wire - 1 month ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Business Wire - 1 month ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Business Wire - 1 month ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Business Wire - 1 month ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Business Wire - 2 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Business Wire - 2 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Zacks Investment Research - 2 months ago

Bellus (BLU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 2 months ago

After establishing a holding in Bellus Health Inc. (NASDAQ:BLU) during the second quarter, billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 A...

Business Wire - 2 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

Business Wire - 2 months ago

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Healt...

Business Wire - 2 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”...

Business Wire - 4 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Business Wire - 4 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...

Zacks Investment Research - 5 months ago

Bellus (BLU) delivered earnings and revenue surprises of 26.32% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...

Zacks Investment Research - 5 months ago

Bellus (BLU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investopedia - 5 months ago

The economy has been tumultuous, but technical analysis helps us see through the static and zero in on the best penny stock opportunities.

Other stocks mentioned: BPT, GNUS, OCC, ZDGE
Newsfile Corp - 6 months ago

San Francisco, California--(Newsfile Corp. - July 13, 2020) - Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The firm is investigating possible...

PRNewsWire - 6 months ago

NEW YORK, July 10, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BELLUS Health Inc. ("BELLUS" or ...

Newsfile Corp - 6 months ago

San Francisco, California--(Newsfile Corp. - July 8, 2020) - Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The firm is investigating possible ...

The Motley Fool - 6 months ago

The company's lead drug has failed a phase 2 trial.

Benzinga - 6 months ago

Canadian biopharma BELLUS Health Inc (NASDAQ: BLU) was losing about three-fourths of its value in Monday's trading session.

Zacks Investment Research - 8 months ago

Bellus (BLU) delivered earnings and revenue surprises of 0.00% and -60.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in BELLUS Health.

Zacks Investment Research - 8 months ago

Bellus (BLU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About BLU

BELLUS Health, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Industry
Biotechnology
Founded
1993
CEO
Roberto Bellini
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
BLU
Full Company Profile

Financial Performance

In 2019, BELLUS Health's revenue was 35,000, a change of 0.00% compared to the previous year's 35,000. Losses were -34.47 million, 279.4% more than in 2018.

Financial numbers in millions CAD.
Financial Statements